List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 47 studies with search of: glioblastoma AND bevacizumab
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Avastin;   Drug: Tarceva;   Drug: Temodar
2 Recruiting Bi-Weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Conditions: Recurrent Glioblastoma Multiforme;   Recurrent Gliosarcoma
Intervention: Drug: temozolomide and bevacizumab
3 Not yet recruiting Avastin/Radiation (XRT)/Temozolomide Followed by Avastin/Temozolomide/Topotecan for Glioblastoma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Gliosarcoma
Intervention: Drug: Avastin in Combination with Radiation and Temozolomide followed by Avastin, Temozolomide, and Topotecan
4 Recruiting RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-Line Treatment of GBM
Condition: Glioblastoma Multiforme
Interventions: Radiation: Radiation therapy;   Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Everolimus
5 Not yet recruiting Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Multiforme
Conditions: Glioblastoma Multiforme;   Gliosarcoma
Intervention: Drug: Avastin in combination with temozolomide and irinotecan
6 Not yet recruiting Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Condition: Brain Tumors
Intervention: Drug: Neuradiab in combination with Bevacizumab (Avastin)
7 Recruiting A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Vorinostat, Bevacizumab and Irinotecan Study
8 Recruiting Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab and Irinotecan and radiotherapy;   Drug: Bevacizumab and Temozolomide and radiotherapy
9 Active, not recruiting Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Drug: temozolomide
10 Recruiting A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Gliosarcoma
Interventions: Other: Taking EIAEDs (enzyme-inducing anticonvulsant medications);   Other: NOT taking EIAEDs
11 Completed A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
Condition: Glioblastoma
Interventions: Drug: bevacizumab;   Drug: irinotecan
12 Recruiting Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
13 Active, not recruiting Avastin in Combo w Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Avastin, & temozolomide
14 Recruiting Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
15 Recruiting Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
16 Suspended Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: dasatinib;   Genetic: fluorescence in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
17 Recruiting Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Radiation: external beam radiation therapy
18 Recruiting A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin];   Drug: Placebo;   Drug: temozolomide;   Radiation: Radiation therapy
19 Recruiting A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Conditions: Glioblastoma;   Astrocytoma
Intervention: Drug: Bevacizumab/Irinotecan
20 Recruiting Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Drug: temozolomide;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services